These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 848578)

  • 1. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM
    Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine agonists in tardive dyskinesia.
    Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
    Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine supersensitivity, endorphin excess, and prostaglandin E1 deficiency: three aspects of the same schizophrenic elephant.
    Horrobin DF
    Schizophr Bull; 1978; 4(4):487-8. PubMed ID: 734362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Adrenergic receptor function in schizophrenia. Receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs.
    Kafka MS; van Kammen DP
    Arch Gen Psychiatry; 1983 Mar; 40(3):264-70. PubMed ID: 6131656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine studies with dopamine agonists in schizophrenia.
    Rotrosen J; Angrist B; Paquin J
    Psychopharmacol Bull; 1978 Jan; 14(1):14-7. PubMed ID: 625529
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet prostaglandin E1 hyposensitivity in schizophrenia: decrease in cyclic AMP formation and in inhibitory effects on aggregation.
    Kaiya H; Ofuji M; Nozaki M; Tsurumi K
    Psychopharmacol Bull; 1990; 26(3):381-4. PubMed ID: 2177206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia and reduced cyclic AMP production: evidence for the role of receptor-linked events.
    Garver DL; Johnson C; Kanter DR
    Life Sci; 1982 Nov; 31(18):1987-92. PubMed ID: 6294425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet monoamine oxidase and the growth hormone response to apomorphine in schizophrenia.
    Malas KL; van Kammen DP; deFraites EA; Brown GM; Gold PW
    Biol Psychiatry; 1983 Feb; 18(2):255-9. PubMed ID: 6830934
    [No Abstract]   [Full Text] [Related]  

  • 16. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.
    Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G
    J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological (H-reflex) studies of patients with tardive dyskinesia.
    Crayton JW; Smith RC; Klass D; Chang S; Ericksen SE
    Am J Psychiatry; 1977 Jul; 134(7):775-81. PubMed ID: 869055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
    Lideman RR; Zlobina GP; Mukhin AG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337
    [No Abstract]   [Full Text] [Related]  

  • 20. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
    Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.